HC Wainwright reissued their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a report released on Wednesday, Benzinga reports. The brokerage currently has a $15.00 price target on the stock. Acumen Pharmaceuticals Stock Performance ABOS stock traded down $0.04 during trading hours on Wednesday, reaching $3.76. The stock had a trading […]

Related Keywords

, Analyst Recommendations For Acumen Pharmaceuticals , Franklin Resources Inc , Acumen Pharmaceuticals , News Ratings For Acumen Pharmaceuticals Daily , Acumen Pharmaceuticals Inc , Knollwood Investment Advisory , Acumen Pharmaceuticals Stock Performance , Free Report , Get Free Report , Springs Capital Management , Capital Management , Acumen Pharmaceuticals Daily ,